Latigo Biotherapeutics Inc(LTGO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LTGO Latigo Biotherapeutics Inc

交易中 10-02 10:06:05 EDT

16.74

+0.05

+0.30%

最高16.80	最低16.38	成交量1.94万
今开16.80	昨收16.69	日振幅2.52%
总市值11.10亿	流通市值3.70亿	总股本6,630万
成交额32.20万	换手率0.09%	流通股本2,212万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LTGO","market":"US","secType":"STK","nameCN":"Latigo Biotherapeutics Inc","latestPrice":16.74,"timestamp":1790949904963,"preClose":16.69,"halted":0,"volume":19359,"delay":0,"changeRate":0.002995805871779338,"floatShares":22121291,"shares":66299347,"eps":-1.676,"marketStatus":"交易中","change":0.05,"latestTime":"10-02 10:06:05 EDT","open":16.8,"high":16.8,"low":16.38,"amount":321991.413273,"amplitude":0.025165,"askPrice":16.92,"askSize":300,"bidPrice":16.73,"bidSize":2,"shortable":3,"etf":0,"ttmEps":-1.676,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1790971200000},"marketStatusCode":2,"adr":0,"listingDate":1786075200000,"exchange":"NASDAQ","adjPreClose":16.69,"preHourTrading":{"tag":"盘前","latestPrice":17.5,"preClose":16.69,"latestTime":"07:41 EDT","volume":6,"amount":103.60999799999999,"timestamp":1790941290044,"change":0.81,"changeRate":0.048532,"amplitude":0.023966},"postHourTrading":{"tag":"盘后","latestPrice":16.69,"preClose":16.69,"latestTime":"19:30 EDT","volume":33779,"amount":563783.11,"timestamp":1790897405872,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.414384},"requestUrl":"/m/hq/s/LTGO/tweets","defaultTab":"tweets","newsList":[{"id":"1194266130","title":"Leerink Partners首次覆盖Latigo Biotherapeutics，给予“跑赢大盘”评级，目标价36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1194266130","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194266130?lang=zh_cn&edition=full","pubTime":"2026-09-01 18:06","pubTimestamp":1788257170,"startTime":"0","endTime":"0","summary":"Leerink Partners宣布正式启动对Latigo Biotherapeutics, Inc.（股票代码：LTGO）的研究覆盖。该机构给予该公司“跑赢大盘”评级，并将其目标股价设定为每股36美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LTGO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657678580","title":"Latigo纳斯达克上市：年亏1.5亿美元 市值11亿美元 恒瑞医药是股东","url":"https://stock-news.laohu8.com/highlight/detail?id=2657678580","media":"雷递网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657678580?lang=zh_cn&edition=full","pubTime":"2026-08-08 21:33","pubTimestamp":1786196029,"startTime":"0","endTime":"0","summary":"生物制药公司Latigo Biotherapeutics（简称：“Latigo”，股票代码：“LTGO”）日前在美国纳斯达克上市。","market":"hk","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260808/6392182162391117981673787.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260808/6392182162391117981673787.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n34595/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["LTGO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657406616","title":"美股异动 | Latigo Biotherapeutics(LTGO.US)登陆美股市场 开盘后股价涨超14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657406616","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657406616?lang=zh_cn&edition=full","pubTime":"2026-08-08 00:17","pubTimestamp":1786119476,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周五，非阿片止痛药开发商Latigo Biotherapeutics(LTGO.US)登陆美股市场，截至发稿，该股涨超14%，报20.53美元。Latigo致力于开发针对Nav1.8钠离子通道的非阿片类止痛药物。其核心候选药物LTG-001是一款口服Nav1.8抑制剂，主要用于治疗中度至重度急性疼痛，包括术后疼痛。这种药物旨在提供媲美阿片类药物的镇痛效果，同时避免成瘾风险。Nav1.8主要表达于外周疼痛感觉神经元，其抑制剂不作用于中枢神经系统，因此不具备成瘾性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477622.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LTGO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126044680","title":"异动解读 | Latigo Biotherapeutics首日上市盘中大涨16.67%，生物科技IPO热潮与创新管线获市场追捧","url":"https://stock-news.laohu8.com/highlight/detail?id=1126044680","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126044680?lang=zh_cn&edition=full","pubTime":"2026-08-07 23:42","pubTimestamp":1786117348,"startTime":"0","endTime":"0","summary":"生物科技公司Latigo Biotherapeutics今日盘中大涨16.67%，成为市场焦点。该股今日在纳斯达克首日上市，开盘后股价迅速走高，表现强劲。此次股价大涨主要得益于Latigo规模扩大的首次公开募股获得市场热烈响应。此外，公司上市正值生物科技板块IPO的黄金窗口期，2026年以来美国生物科技和制药企业IPO加权平均回报率高达55%，市场对具备差异化临床数据和明确市场机会的平台型公司兴趣浓厚，为Latigo的股价表现提供了有力支撑。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["LTGO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656539622","title":"非阿片止痛药新锐Latigo(LTGO.US)IPO拟最高募资2.88亿美元，Nav1.8抑制剂剑指福泰制药(VRTX.US)百亿市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2656539622","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656539622?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:59","pubTimestamp":1785833974,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBB","BK4533","PBE","IE00BFTCPJ56.SGD","KCE","LU0234570918.USD","LU0823416689.USD","LU0289739699.SGD","LU1585245621.USD","VRTX","LU2468319806.SGD","BK4532","BK4127","LU1674673428.USD","LU2362541513.USD","GNMX","LU1093756168.USD","REDS","IE00B19Z3581.USD","LU2456880835.USD","IPOS","LU1778281490.HKD","IE00BJJMRZ35.SGD","LU0256863811.USD","BK4585","IE0002141913.USD","BK4139","IE00B4R5TH58.HKD","LU2324357040.USD","IDNA","FRHC","LU0058720904.USD","LU0417517546.SGD","SGXZ57979304.SGD","LU2362541273.HKD","LU0889565916.HKD","BIB","IE00BJT1NW94.SGD","LU1430594728.SGD","BBH","BK4588","IE00B19Z3B42.SGD","IE00B19Z9P08.USD","TBXU","SG9999013999.USD","LU1093756325.SGD","IBBQ","IE00B19Z9Z06.USD","IE00BZ9MQY76.HKD","LTGO"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.latigobio.com","stockEarnings":[{"period":"1week","weight":-0.0602},{"period":"1month","weight":-0.2502},{"period":"3month","weight":-0.0728},{"period":"ytd","weight":-0.0728}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":0.0029},{"period":"3month","weight":0.0258},{"period":"6month","weight":0.1649},{"period":"1year","weight":0.1429},{"period":"ytd","weight":0.1204}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Latigo Biotherapeutics, Inc.于2018年11月在特拉华州注册成立。该公司是一家临床阶段的生物制药公司，致力于开发创新的非阿片类镇痛药物，旨在抑制疼痛传播而不会产生成瘾风险。其管道主要集中在Nav1.8抑制剂，初步开发努力针对肌肉骨骼疼痛。该公司还计划探索涉及疼痛传递的其他离子通道靶点，以建立最广泛的疼痛疗法管道之一。","exchange":"NASDAQ","name":"Latigo Biotherapeutics Inc","nameEN":"Latigo Biotherapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Latigo Biotherapeutics Inc(LTGO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Latigo Biotherapeutics Inc(LTGO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Latigo Biotherapeutics Inc,LTGO,Latigo Biotherapeutics Inc股票,Latigo Biotherapeutics Inc股票老虎,Latigo Biotherapeutics Inc股票老虎国际,Latigo Biotherapeutics Inc行情,Latigo Biotherapeutics Inc股票行情,Latigo Biotherapeutics Inc股价,Latigo Biotherapeutics Inc股市,Latigo Biotherapeutics Inc股票价格,Latigo Biotherapeutics Inc股票交易,Latigo Biotherapeutics Inc股票购买,Latigo Biotherapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Latigo Biotherapeutics Inc(LTGO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Latigo Biotherapeutics Inc(LTGO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}